Recently added articles from Worldwide Biotech:
ELIGEN WITH GLP-1 AND PYY3-36 SUPPRESSES APPETITE.(Clinical report)
Jul 01, 2009 ... Emisphere Technologies, Inc. (NASDAQ: EMIS) has announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen Technology on appetite suppression. The study was conducted at the University Hospital ...
AVITA GETS AU$2M FROM US MILITARY TO SPEED DEVICE APPROVAL.
Jul 01, 2009 ... Avita Medical Ltd (ASX: AVH) has been awarded US$1.45 million (AU$2 million) from the US Armed Forces Institute of Regenerative Medicine (AFIRM) to accelerate approval of the company's ReCell Autologous Cell Harvesting device in the US market. The intent of all parties is to make the ...
CYTOPIA PROGRAM REACHES MILESTONE AT CANCER THERAPEUTICS.
Jul 01, 2009 ... Cytopia Limited (ASX:CYT) has announced significant progress by Cancer Therapeutics CRC Pty Ltd (CTx) towards the identification of a pre-clinical drug candidate. This candidate is based on intellectual property licensed from Cytopia to CTx. Cytopia and CTx entered into an ...
PROTEO/MAYOLY SPINDLER FORM DRUG DEVELOPMENT PARTNERSHIP.
Jul 01, 2009 ... Protea Biosciences, Inc., Morgantown, W. Va., a leader in the development of new protein technology, has entered into a drug development partnership with LABORATOIRES MAYOLY SPINDLER (Mayoly), a European pharmaceutical company based in France, that specializes in Gastroenterology ...
IRISH GASTROENTEROLOGY RESEARCHERS PIONEER IBS TREATMENTS.
Jun 01, 2009 ... Second only to the common cold as the leading source of workplace absenteeism in the Western world, Irritable Bowel Syndrome (IBS) is suffered by between 15 and 20 percent of all adolescents and adults in Western populations and 40 percent of those have symptoms severe or frequent enough ...
BAYER/REGENERON EXTEND PROGRAM FOR VEGF TRAP-EYE.
Jun 01, 2009 ... Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) have announced that the companies are extending their global development program for VEGF Trap-Eye, an investigational agent for the treatment of certain eye diseases, to include Central Retinal Vein Occlusion (CRVO) ....
INIMEX BEGINS CLINICAL STUDY OF INNATE DEFENSE REGULATOR.
Jun 01, 2009 ... Inimex Pharmaceuticals, Vancouver, BC,, has announced that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study of IMX942 being performed for Inimex in ...
CISBIO BIOASSAYS UNVEILS TAG-LITE FOR ASSAY DEVELOPMENT.
Jun 01, 2009 ... Cisbio Bioassays (http://www.htrf.com), member of IBA group and global developer of HTRF (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, has launched Tag-lite, its new cellular platform for cell surface receptor study and ...
DIAMYD MEDICAL LICENSES NOVEL PAIN PRODUCT.
May 01, 2009 ... Diamyd Medical has acquired an exclusive license for Endomorphin technology that may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes. "In addition to this newly acquired Endomorphin technology, and our exclusive licenses for GAD, we also ...
EVOTEC REPORTS RESULTS OF PHASE II PROOF-OF-CONCEPT STUDY WITH EVT 302.
May 01, 2009 ... Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC), Hamburg, Germany, has announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B), as an aid to smoking cessation. EVT 302 ...
SANOFI-AVENTIS TO ACQUIRE BIPAR SCIENCES.
May 01, 2009 ... Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) has signed a binding agreement for the acquisition of BiPar Sciences, Inc. ("BiPar"), a privately held US biopharmaceutical company, developing novel tumor- selective approaches for the treatment of different types of cancers. BiPar is ...
BIOWA LICENSES POTELLIGENT TECHNOLOGY TO SANOFI-AVENTIS.
May 01, 2009 ... BioWa, Inc. Princeton, N.J. has entered into a license agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY), providing the global healthcare company with access to BioWa's POTELLIGENT(R) Technology platform for the research, development and commercialization of their antibody ...
CAN-FITE BIOPHARMA TO INITIATE CF102 TRIAL FOR LIVER CANCER.
May 01, 2009 ... Can-Fite BioPharma (TASE:CFBI), Petach Tikva, Israel, a biotechnology company traded on the Tel Aviv Stock Exchange, has announced that, following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee, a phase I/II clinical trial with CF102 for the treatment of liver ...
SURVIVAL INPROVEMENT REPORTED IN SATRAPLATIN SPARC TRIAL.
Apr 01, 2009 ... GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) has announced that data from the double-blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) was presented at the 2009 American Society for Clinical Oncology (ASCO) ...
OREXO'S ASTRAL GETS TWO MORE EU MARKET APPROVALS.
Apr 01, 2009 ... Orexo (NASDAQ-OMX:ORX), has announced that Abstral has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain. AbstralTM is expected to be launched during the second half of 2009 in France and Spain, ...
BAVARIAN NORDIC AGREES ON PATHAWAY FOR INVAMUNE LICENSURE.
Apr 01, 2009 ... Following the completion of the Phase II clinical development of IMVAMUNE(R), a third-generation smallpox vaccine, Bavarian Nordic has held an end of Phase II meeting with the FDA to discuss the Phase III development. The meeting was a success and there was an open and highly constructive ...
EPISTEM SIGNS R&D COLLABORATION WITH NOVARTIS.
Apr 01, 2009 ... Epistem Plc (LSE:EHP) the UK biotechnology and research services company has signed a research and development collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas. The collaboration combines Epistem's stem cell expertise ...
JPT LAUNCHES "PEPTRACK" FOR T-CELL ASSAYS IN VACINE DEVELOPMENT.
Mar 01, 2009 ... JPT Peptide Technologies GmbH (JPT), Berlin, a wholly-owned subsidiary of Jerini AG (Frankfurt:JI4), has launched its new product line: PepTrack(tm). Designed for peptides in T-cell assays (ELISPOT, CFC, ICS and others), this approach represents the most efficient technique for producing ...
LEUCHEMIX PROVIDES UPDATE ON CANCER TRIAL.
Mar 01, 2009 ... CombiMatrix Corporation (Nasdaq:CBMX), Mukilteo, Wash., has announced that Leuchemix provided additional information regarding the initial clinical trial of its novel anticancer drug LC-1. The initial trial is being performed at Cardiff University in the United Kingdom under the ...
KAHR MEDICAL RAISES $500K FROM HADSIT BIO-HOLDINGS/ISRAEL MINISTRY.
Mar 01, 2009 ... KAHR Medical, Jerusalem, Israel, a Hadasit Bio-Holdings (HBL, TASE: HDST) portfolio company, has raised $500 thousand from HBL and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel (OCS). KAHR Medical's drug development pipeline is built around the ...